Statistical Issues in Drug Development / Edition 2

Hardcover (Print)
Used and New from Other Sellers
Used and New from Other Sellers
from $119.86
Usually ships in 1-2 business days
(Save 14%)
Other sellers (Hardcover)
  • All (8) from $119.86   
  • New (6) from $119.86   
  • Used (2) from $145.74   

Overview

Drug development is the process of finding and producing therapeutically useful pharmaceuticals, turning them into safe and effective medicine, and producing reliable information regarding the appropriate dosage and dosing intervals. With regulatory authorities demanding increasingly higher standards in such developments, statistics has become an intrinsic and critical element in the design and conduct of drug development programmes.

Statistical Issues in Drug Development presents an essential and thought provoking guide to the statistical issues and controversies involved in drug development. 

This highly readable second edition has been updated to include:

  • Comprehensive coverage of the design and interpretation of clinical trials.
  • Expanded sections on missing data, equivalence, meta-analysis and dose finding.
  • An examination of both Bayesian and frequentist methods.
  • A new chapter on pharmacogenomics and expanded coverage of pharmaco-epidemiology and pharmaco-economics.
  • Coverage of the ICH guidelines, in particular ICH E9, Statistical Principles for Clinical Trials.

It is hoped that the book will stimulate dialogue between statisticians and life scientists working within the pharmaceutical industry. The accessible and wide-ranging coverage make it essential reading for both statisticians and non-statisticians working in the pharmaceutical industry, regulatory bodies and medical research institutes. There is also much to benefit undergraduate and postgraduate students whose courses include a medical statistics component.

A brief history of statistics for drug developers, design & interpretation of clinical trials as seen by a statistician.

Read More Show Less

Editorial Reviews

From the Publisher
For all his contributions to the development and exposition of medical statistics Stephen Senn is awarded the 2009 Bradford Hill Medal by the Royal Statistical Society.

• This book is a thought provoking, intriguing, and often challenging read. The author is unafraid to tackle weighty philosophical and paradigmatic issues, and he generally does so with great skill and insight. ...this excellent book should serve to inspire both statisticians and life scientists.? (Journal of the American Statistical Association, September 2009)

"For statisticians, this should be required reading for anyone considering or starting out on a career in clinical drug development. I am also quite sure that most experienced statisticians would find this a useful book to dip into on occasion ... . This book will not disappoint." (Journal of the Royal Statistical Society: Series A (Statistics in Society), April 2009)

"This book is an outstanding effort from a statistician of heroic proportions. Someone like me is only capable of sitting on the curb and applauding wildly." (Journal of Biopharmaceutical Statistics, Volume 19, Issue 1, 2009)

Read More Show Less

Product Details

  • ISBN-13: 9780470018774
  • Publisher: Wiley
  • Publication date: 1/28/2008
  • Series: Statistics in Practice Series
  • Edition description: New Edition
  • Edition number: 2
  • Pages: 524
  • Product dimensions: 6.81 (w) x 9.67 (h) x 1.32 (d)

Meet the Author

Stephen Senn has worked for the NHS in England, as a lecturer in Scotland and in drug development in Switzerland (with CIBA-Geigy). Until recently he was Professor of Pharmaceutical and Health Statistics at University College London but since September 2003 he has been  Professor of Statistics at Glasgow University. His books, Cross-over Trials in Clinical Research (1993, 2nd edition 2002) and Statistical Issues in Drug Development (1997) are published by Wiley and his latest book, Dicing with Death (2003) by Cambridge University Press. In 2001, he was the first recipient of the George C Challis award for biostatistics of the University of Florida. He is a member of the editorial boards of Statistics in Medicine, Statistical Methods in Medical Research, Pharmaceutical Statistics and Applied Clinical Trials and is a section editor for the Wiley Statistics in Practice series.

Read More Show Less

Read an Excerpt

Click to read or download

Read More Show Less

Table of Contents

Preface to the Second Edition.

Preface to the First Edition.

Acknowledgements.

1. Introduction.

1.1 Drug development.

1.2 The role of statistics in drug development.

1.3 The object of this book.

1.4 The author’s knowledge of statistics in drug development.

1.5 The reader and his or her knowledge of statistics.

1.6 How to use the book.

Part 1: Four Views of Statistics in Drug Development: Historical, Methodological, Technical and Professional.

2. A Brief and Superficial History of Statistics for Drug Developers.

2.1 Introduction.

2.2 Early Probabilists.

2.3 James Bernoulli (1654–1705).

2.4 John Arbuthnott (1667–1753).

2.5 The mathematics of probability in the late 17th, the 18th and early 19th centuries.

2.6 Thomas Bayes (1701–1761).

2.7 Adolphe Quetelet (1796–1874).

2.8 Francis Galton (1822–1911).

2.9 Karl Pearson (1857–1936).

2.10 ‘Student’ (1876–1937).

2.11 R.A. Fisher (1890–1962).

2.12 Modern mathematical statistics.

2.13 Medical statistics.

2.14 Statistics in clinical trials today.

2.15 The current debate.

2.16 A living science.

2.17 Further reading.

3. Design and Interpretation of Clinical Trials as Seen by a Statistician.

3.1 Prefatory warning.

3.2 Introduction.

3.3 Defining effects.

3.4 Practical problems in using the counterfactual argument.

3.5 Regression to the mean.

3.6 Control in clinical trials.

3.7 Randomization.

3.8 Blinding.

3.9 Using concomitant observations.

3.10 Measuring treatment effects.

3.11 Data generation models.

3.12 In conclusion.

3.13 Further reading.

4. Probability, Bayes, P-values, Tests of Hypotheses and Confidence Intervals.

4.1 Introduction.

4.2 An example.

4.3 Odds and sods.

4.4 The Bayesian solution to the example.

4.5 Why don’t we regularly use the Bayesian approach in clinical trials?

4.6 A frequentist approach.

4.7 Hypothesis testing in controlled clinical trials.

4.8 Significance tests and P-values.

4.9 Confidence intervals and limits and credible intervals.

4.10 Some Bayesian criticism of the frequentist approach.

4.11 Decision theory.

4.12 Conclusion.

4.13 Further reading .

5. The Work of the Pharmaceutical Statistician.

5.1 Prefatory remarks.

5.2 Introduction.

5.3 In the beginning.

5.4 The trial protocol.

5.5 The statistician’s role in planning the protocol.

5.6 Sample size determination.

5.7 Other important design issues.

5.8 Randomization.

5.9 Data collection preview.

5.10 Performing the trial.

5.11 Data analysis preview.

5.12 Analysis and reporting.

5.13 Other activities.

5.14 Statistical research.

5.15 Further reading.

Part 2: Statistical Issues: Debatable and Controversial Topics in Drug Development.

6. Allocating Treatments to Patients in Clinical Trials.

6.1 Background.

6.2 Issues.

References.

6.A Technical appendix.

7. Baselines and Covariate Information.

7.1 Background.

7.2 Issues.

7.A Technical appendix.

8. The Measurement of Treatment Effects.

8.1 Background.

8.2 Issues.

8.A Technical appendix. 

9. Demographic Subgroups: Representation and Analysis.

9.1 Background.

9.2 Issues.

9.A Technical appendix. 

10. Multiplicity.

10.1 Background.

10.2 Issues.

10.A Technical appendix.

11. Intention to Treat, Missing Data and Related Matters.

11.1 Background.

11.2 Issues.

11.A Technical appendix.

12. One-sided and Two-sided Tests and Other Issues to Do with Significance and P-values.

12.1 Background.

12.2 Issues.

13. Determining the Sample Size.

13.1 Background.

13.2 Issues.

14. Multicentre Trials.

 14.1 Background.

14.2 Issues.

14.A Technical appendix.

15. Active Control Equivalence Studies.

15.1 Background.

15.2 Issues.

15.A Technical appendix.

16. Meta-Analysis.

16.1 Background.

16.2 Issues.

16.A Technical appendix.

17. Cross-over Trials.

17.1 Background.

17.2 Issues. 

18. n-of-1 Trials.

18.1 Background.

18.2 Issues. 

19. Sequential Tr4ials.

19.1 Background.

19.2 Issues.

20. Dose-finding.

20.1 Background.

20.2 Issues.

21. Concerning Pharmacokinetics and Pharmacodynamics.

21.1 Background.

21.2 Issues.

22. Bioequivalence Studies.

22.1 Background.

22.2 Issues.

23. Safety Data, Harms, Drug Monitoring and Pharmaco-epidemiology.

23.1 Background.

23.2 Issues.

24. Pharmaco-economics and Portfolio Management.

24.1 Background.

24.2 Issues. 

25. Concerning Pharmacogenetics, Pharmacogenomics and Related Matters.

25.1 Background.

25.2 Issues.

25.A Technical appendix.

Glossary.

Index.

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)